Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:1945219" >
A 1-year, randomize...
-
Winblad, BKarolinska Institutet
(författare)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
- Artikel/kapitelEngelska2001
Förlag, utgivningsår, omfång ...
-
2001-08-14
-
Ovid Technologies (Wolters Kluwer Health),2001
Nummerbeteckningar
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:1945219
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1945219URI
-
https://doi.org/10.1212/wnl.57.3.489DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD.Methods: Patients (n = 286; mean age, 72.5 years) with possible or probable AD from five Northern European countries were randomized to receive either donepezil (n = 142; 5 mg/day for 28 days, followed by 10 mg/day) or placebo (n = 144) for 1 year.Results: The study was completed by 66.9% of the donepezil- and 67.4% of the placebo-treated patients. The benefit of donepezil over placebo was demonstrated by the Gottfries-Bråne-Steen (a global assessment for rating dementia symptoms) total score at weeks 24, 36, and 52 (p < 0.05) and at the study end point (week 52, last observation carried forward; p = 0.054). Advantages of donepezil over placebo were also observed in cognition and activities of daily living (ADL) assessed by the Mini-Mental State Examination at weeks 24, 36, and 52, and the end point (p < 0.02) and by the Progressive Deterioration Scale at week 52 and the end point (p < 0.05). Adverse events (AE) were recorded for 81.7% of donepezil- and 75.7% of placebo-treated patients, with 7% of donepezil- and 6.3% of placebo-treated patients discontinuing because of AE. Treatment response to donepezil was not predicted by APOE genotype or sex in this population.Conclusion: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Engedal, K
(författare)
-
Soininen, H
(författare)
-
Verhey, F
(författare)
-
Waldemar, G
(författare)
-
Wimo, AKarolinska Institutet
(författare)
-
Wetterholm, AL
(författare)
-
Zhang, R
(författare)
-
Haglund, A
(författare)
-
Subbiah, P
(författare)
-
Karolinska Institutet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Neurology: Ovid Technologies (Wolters Kluwer Health)57:3, s. 489-4950028-38781526-632X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Winblad, B
-
Engedal, K
-
Soininen, H
-
Verhey, F
-
Waldemar, G
-
Wimo, A
-
visa fler...
-
Wetterholm, AL
-
Zhang, R
-
Haglund, A
-
Subbiah, P
-
visa färre...
- Artiklar i publikationen
-
Neurology
- Av lärosätet
-
Karolinska Institutet